PT  - JOURNAL ARTICLE
AU  - Rousculp, Matthew
AU  - Ziemiecki, Ryan
AU  - Marchese, Anthony M.
TI  - Protein Vaccine Demonstrates Less Reactogenicity than mRNA – A Real World Study
AID  - 10.1101/2023.05.31.23290594
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.31.23290594
4099  - http://medrxiv.org/content/early/2023/06/04/2023.05.31.23290594.short
4100  - http://medrxiv.org/content/early/2023/06/04/2023.05.31.23290594.full
AB  - A prospective, observational study investigated the burden and impact of vaccine reactogenicity in adults from the United States and Canada who received an approved/authorized mRNA COVID-19 vaccine or the Novavax COVID vaccine as a booster dose. As part of the real-world study, reactogenic events captured via patient symptom diaries were compared. Results demonstrated that the overall percentage of Novavax COVID booster recipients experiencing any reactogenicity event (77.6%) was lower than that of mRNA doses (95.9%).Competing Interest StatementMR and AMM are employees and shareholders of Novavax Inc.Funding StatementThis work was supported by Novavax, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Advarra institutional review board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRequests for data will be considered.